A 7-year-old boy with acute lymphoblastic leukemia (ALL) in second remission received an allogeneic PBSCT from his HLA-matched sister. Acute grade II graftversus-host disease (GVHD) resolved with corticosteroids. Chronic GVHD in the skin and oral mucosa at around day 60 responded to corticosteroids and cyclosporin A. At 6 months after the transplant, he developed hepatic dysfunction with elevated serum transaminases and gamma-globulin. Liver biopsy revealed chronic inflammation with lymphocytes and plasma cells in portal areas without destruction of bile ducts, suggesting autoimmune hepatitis. While rare, autoimmune hepatitis should be considered a potential long-term complication in patients with hepatic dysfunction in the late post-transplant phase.
autoimmune hepatitis; allogeneic PBSCT; chronic hepatic dysfunction Chronic or intermittent liver enzyme elevation is a common problem in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). There are several possible causes of chronic hepatic dysfunction in the late post-transplant phase. More than 6 months after allogeneic HSCT, liver disease may be caused by chronic graft-versus-host disease (GVHD), the drugs used for GVHD prophylaxis and/or treatment, viral infection, vascular endothelial cell damage, and iron overload, especially in patients with severe aplastic anemia. 1 The most frequent cause is chronic GVHD, and this usually manifests as cholestasis. Furthermore, isolated liver involvement due to chronic GVHD without clinical signs or symptoms of other organ involvement is uncommon. Cyclosporin A (CsA) can cause necrosis of hepatocytes. Viral infection can often lead to hepatic failure and cirrhosis, the incidence of which has recently been reduced by the use of well-screened blood products. Autoimmunemediated hepatocyte damage is rare.
The relation between HSCT and autoimmune disease is complex. While autoimmune disease can be cured by HSCT, 2 de novo autoimmune disease can be induced by the transplantation procedure. 3 This may develop via an imbalance in the immune system due to insufficient numbers or inadequate function of suppressor T cells in the early postgraft period, delayed recovery of regulatory T cells, or subsequent activation of autoreactive T cells.
We describe an allogeneic peripheral blood stem cell transplant (PBSCT) complicated by a significant elevation of serum AST and ALT and gamma-globulin that was histologically confirmed to be autoimmune hepatitis.
Case report
A 7-year-old boy with acute lymphoblastic leukemia received remission induction chemotherapy in October 1998, and achieved complete remission. However, relapse occurred in the central nervous system (CNS) and bone marrow (BM) in October 1999, during maintenance chemotherapy. Following systemic reinduction chemotherapy and treatment for CNS disease, consisting of craniospinal irradiation and intrathecal chemotherapy, he was transferred to our hospital for allogeneic PBSCT from his HLA-matched 5-year-old sister in March 2000. Patient and donor serology tests for hepatitis A, B and C viruses were negative, and liver function tests were normal. The procedures for PBSC harvest were explained to the donor and her parents, and written informed consent was obtained from the parents. For mobilization of PBSC, G-CSF was administered to the donor subcutaneously at a dose of 10 mg/kg for 5 days. PBSC were collected by aphereses on days 5 and 6 of G-CSF treatment and stored in a À1351C deep freezer until transplantation. The patient received pretransplant conditioning chemotherapy consisting of busulfan (4 mg/kg Â 4 days) and L-PAM (60 mg/ kg Â 3 days). For GVHD prophylaxis, 3 mg/kg/day CsA starting on day À1 and 1 mg/kg/day methylprednisolone (mPDN) starting on day 5 were given. Thawed PBSCs containing 3.8 Â 10 /l. Grade II cutaneous acute GVHD was observed on day 14, but this soon resolved with an increased dose of mPDN. On day 60, lichenoid lesions of the oral mucosa and skin eruption developed, and were diagnosed as chronic GVHD. Chronic GVHD responded to oral prednisolone (PDN) and CsA, and he was well until day 180, when his hepatic enzyme levels began to increase (Figure 1 ). The peak levels of serum transaminase were seen on day 236: ALT 811, AST 862, ALP 2081, g-GTP 121 IU/l, total bilirubin 2.2 mg/dl. Serum levels of total protein and gamma-globulin were markedly elevated up to 9.3 g/dl and 3500 mg/dl, respectively, although he had not received intravenous immunoglobulin since day 120. The titer of antinuclear antibody was 1:160 and that of antimitochondrial antibody was 1:80. Other autoimmune markers were negative. Serological tests for infection with hepatitis A, B and C viruses were negative. RT-PCR for varicella zoster virus (VZV) and herpes simplex virus (HSV) were all negative. A cytomegalovirus (CMV) antigenemia screen was also negative. At that time, the manifestations of chronic GVHD in the skin and oral mucosa resolved. Liver biopsy was performed on day 194 and revealed chronic portal inflammation with interface activity infiltrated by lymphocytes and plasma cells. Interlobular bile ducts were not damaged and no significant necrosis or inflammation was observed in the lobules (Figure 2a and b) . A diagnosis of autoimmune hepatitis was made. CsA was discontinued because of presumed hepatic injury and the absence of chronic GVHD. PDN (1 mg/kg/day) and ursodeoxycholic acid were started on day 236. With PDN treatment, his hepatic function gradually improved, and the serum ALT decreased to 53 IU/l, serum AST to 75 IU/l and serum gamma-globulin to 1360 mg/dl on day 432. However, he became obese, the serum levels of triglyceride became very high, and signs of osteoporosis appeared. Therefore, PDN was tapered until day 666, and was converted to tacrolimus. However, the serum transaminase and gamma-globulin levels began to increase again on day 796: ALT 594 IU/l, AST 586 IU/l and IgG 2820 mg/dl. PDN was restarted at a dose of 1 mg/kg/day on day 801, and the liver function gradually improved.
Discussion
The mechanism of autoimmune phenomena following stem cell transplantation is unclear. The presence of conditioning-induced thymic damage might interfere with negative selection of autoreactive cells and thereby facilitate the development of cellular and humoral autoreactivity. A T1/ T2 cell imbalance, which usually occurs post-transplant, might contribute to the development of autoantibodies. A predominance of T2 cells may induce an autoimmune phenomenon. 4 In autoimmune hepatitis, hepatocytes become injured due to various causes, such as viral infection or a drug, and become antigenic, leading to a selfperpetuating antigen-antibody response, with subsequent chronic liver disease. Autoantibodies are frequently observed after HSCT, particularly in patients with chronic GVHD. No correlation has been demonstrated between these antibodies and GVHD activity. The most commonly detected antibodies are rheumatoid factor and antinuclear, antismooth muscle, and antimitochondrial antibodies. 5 Generally, patients are asymptomatic and no therapy is indicated for this finding alone. When symptoms appear, hemolytic anemia and thrombocytopenia are common, and are often associated with chronic GVHD. On the other hand, autoimmune diseases such as multiple sclerosis, systemic lupus erythematosis (SLE), rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) can be cured with HSCT. 6 The development and cure of autoimmune disease are opposing processes. Further, with regard to stem cell source, the incidence of chronic GVHD might be high following allogeneic PBSCT compared to allogeneic BMT. 7 However, there are no data available regarding stem cell source in the context of autoimmune phenomena. The use of PBSC might contribute to the development of autoimmune hepatitis because G-CSF-mobilized grafts contain predominantly T2 lymphocytes. 8 . Immunological recovery following stem cell transplantation reflects a recapitulation of ontogeny. Advances in our understanding of the human immune system and immunological ontogeny following HSCT are encouraging.
Occasionally, autoimmune hepatitis develops after liver transplantation in pediatric patients with congenital liver disease such as biliary atresia. 9 Cyclosporin has been implicated in the development of autoimmune hepatitis, and the median interval after liver transplantation was 4 years. The onset in this case was earlier than that in autoimmune hepatitis developing after liver transplantation. Although autoimmune hepatitis after HSCT is rare, especially in the pediatric population, it should be included in the differential diagnosis for patients with hepatic dysfunction in the late post-transplant phase, and should be considered a long-term complication. The differences between post-transplant autoimmune hepatitis and hepatic GVHD are summarized in Table 1 . There have been few reports on the prognosis and treatment of autoimmune hepatitis developing after HSCT. Once the diagnosis has been confirmed, clarification is required as whether the treatment should be identical to that of nontransplant patients who develop autoimmune hepatitis. Mortality rates of up to 80% have been reported in untreated nontransplant patients with a greater than five-fold elevation in serum AST activity, or a greater than twofold increase in the gamma-globulin concentration. 10 Nontransplant patients with a serum AST or ALT exceeding 10 times the upper normal value, histologic evidence of bridging or multilobular necrosis, and/or severe hepatic and extrahepatic symptoms, should always be treated. Autoimmune hepatitis is the only type of hepatitis that responds to corticosteroids. In our case, hepatic dysfunction responded well to PDN treatment. A sustained response to therapy may result in a substantial regression of fibrosis even in advanced cases. Since there was only one patient, it is difficult to speculate on the natural history of this phenomenon. The rapid withdrawal of immune suppression leads to disease relapse in many patients, as in our case. Long-term corticosteroid treatment might be necessary. However, the risk/benefit ratio for the long-term use of corticosteroids for this indication should be evaluated. Table 1 The differences between post-transplant autoimmune hepatitis and hepatic GVHD Autoimmune hepatitis after allogeneic PBSCT T Ogose et al
